Skip to main content

24-05-2024 | Lung Cancer | Clinical Trial Summary | Article

Updated May 2024

At a glance: The KEYNOTE lung cancer trials

Author: Dr. Shreeya Nanda

The PD-1 inhibitor pembrolizumab is being investigated in multiple KEYNOTE trials across different tumor types, either alone or as part of various combinations, leading to a prodigious amount of information.

Related topics